Anti-Müllerian Hormone (AMH)
Anti-Müllerian Hormone (AMH) is a TGF-β superfamily glycoprotein produced by granulosa cells and Sertoli cells that serves as a gold-standard biomarker for ovarian reserve assessment, PCOS diagnosis, and male reproductive function. Recombinant AMH is under preclinical investigation as a non-hormonal contraceptive.
Anti-Müllerian Hormone (AMH), also known as Müllerian-inhibiting substance (MIS), is a dimeric glycoprotein belonging to the transforming growth factor-beta (TGF-β) superfamily. In females, AMH is produced by granulosa cells of preantral and small antral follicles and serves as the most reliable serum biomarker for ovarian reserve.
Overview
AMH is a 560-amino acid precursor protein that undergoes proteolytic cleavage to yield a biologically active C-terminal dimer. The mature hormone signals through a dedicated type II receptor (AMHR2), which recruits type I receptors ALK2 or ALK3 to activate the Smad1/5/8 intracellular signaling pathway. In the ovary, AMH inhibits recruitment of primordial follicles into the growing pool and modulates FSH sensitivity of developing follicles, thereby regulating the rate of follicular depletion. In the male fetus, AMH produced by Sertoli cells causes regression of Müllerian ducts (the precursors of the uterus, fallopian tubes, and upper vagina), a critical step in male sexual differentiation.
Serum AMH levels reflect the size of the remaining ovarian follicle pool and decline progressively with age, becoming undetectable after menopause. This property has made AMH the most widely used biomarker in reproductive endocrinology, with applications spanning IVF cycle management, fertility preservation counseling, PCOS diagnosis, and oncofertility assessment.
Mechanism of Action
AMH exerts its biological effects through a well-characterized receptor signaling cascade:
- AMHR2 binding: AMH binds its dedicated type II serine/threonine kinase receptor (AMHR2), expressed on granulosa cells, Sertoli cells, and Müllerian duct mesenchyme
- Type I receptor recruitment: Ligand-bound AMHR2 recruits and phosphorylates type I receptors ALK2 (ACVR1) or ALK3 (BMPR1A)
- Smad signaling: Activated ALK2/3 phosphorylates Smad1/5/8, which complex with Smad4 and translocate to the nucleus to regulate target gene transcription
- Follicular inhibition: In the ovary, AMH inhibits primordial follicle recruitment and reduces FSH sensitivity of growing follicles, serving as a brake on follicular depletion
- Müllerian duct regression: In the male embryo, AMH triggers apoptosis and epithelial-to-mesenchymal transition in Müllerian duct cells, causing irreversible regression by week 10 of gestation
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Ovarian Reserve Assessment
AMH has become the gold standard biomarker for ovarian reserve, surpassing FSH, estradiol, and inhibin B in predictive accuracy. Serum AMH correlates directly with antral follicle count (AFC) and predicts ovarian response to controlled ovarian stimulation in IVF cycles. La Marca et al. (2010) demonstrated that AMH is the most consistent predictor of poor and hyper-response in assisted reproduction, enabling individualized gonadotropin dosing. Unlike FSH, AMH shows minimal intercycle variability and can be measured on any day of the menstrual cycle, making it a more practical clinical tool. Low AMH values (<1.0 ng/mL) predict diminished ovarian reserve and reduced IVF success rates, while very high levels may indicate risk of ovarian hyperstimulation syndrome.
Male Sertoli Cell Function & Cryptorchidism Marker
In males, AMH is produced by Sertoli cells from fetal life through puberty, when rising testosterone levels suppress its expression. Serum AMH serves as a marker of Sertoli cell number and function in prepubertal boys. In the evaluation of cryptorchidism and disorders of sex development, detectable AMH confirms the presence of functional testicular tissue without requiring surgical exploration. Undetectable AMH in a phenotypic male with bilateral nonpalpable testes strongly suggests anorchia. AMH also aids in distinguishing constitutional delay from hypogonadotropic hypogonadism in adolescent males.
Oncofertility
AMH is central to fertility preservation counseling before gonadotoxic cancer treatment. Pre-treatment AMH levels predict the likelihood of post-chemotherapy ovarian recovery and inform decisions about oocyte/embryo cryopreservation. Anderson et al. (2013) showed that post-chemotherapy AMH levels predict long-term ovarian function and can identify women at risk for premature ovarian insufficiency. Serial AMH monitoring after cancer treatment provides the earliest indication of ovarian reserve recovery, as AMH rises before resumption of menstrual cycles. This application has become integral to multidisciplinary oncofertility programs.
AMH-Based Contraception Research
Recombinant AMH is under investigation as a potential non-hormonal contraceptive. Kano et al. (2017) demonstrated that sustained delivery of recombinant AMH in mice depletes the growing follicle pool, inducing reversible anovulation without affecting estrous cycling or bone density. Unlike hormonal contraceptives, AMH-based approaches would not suppress the hypothalamic-pituitary-ovarian axis, potentially avoiding estrogen-related side effects (thromboembolism, mood changes). The approach targets the ovary directly through its physiological receptor, offering a novel mechanism distinct from all existing contraceptive methods. Preclinical studies continue to optimize delivery systems for sustained AMH exposure.
Granulosa Cell Tumors
AMH serves as a specific diagnostic and surveillance biomarker for granulosa cell tumors (GCTs) of the ovary. Serum AMH is elevated in the majority of GCT patients and falls to undetectable levels after complete surgical resection. Rising AMH during follow-up precedes clinical recurrence by months to years, making it the most sensitive marker for GCT surveillance. Inhibin B is used as a complementary marker, but AMH offers superior specificity. This application has significantly improved long-term monitoring of patients with these rare but recurrence-prone tumors.
PCOS Diagnosis
Polycystic ovary syndrome is associated with elevated serum AMH levels, often 2-3 times higher than age-matched controls. This elevation reflects the increased number of small antral follicles characteristic of PCOS. Dewailly et al. (2014) proposed that AMH could serve as a surrogate for ultrasound-based polycystic ovarian morphology in PCOS diagnosis, particularly in settings where high-quality transvaginal ultrasound is unavailable. Elevated AMH has been incorporated into modified diagnostic criteria for PCOS and correlates with disease severity, hyperandrogenism, and anovulation. Serial AMH measurements may also track treatment response in PCOS patients receiving ovulation induction therapy.
Safety Profile
AMH is an endogenous biomarker, and serum measurement for diagnostic purposes carries no safety concerns beyond standard venipuncture. The assay is well standardized across platforms (Elecsys, Access, picoAMH), though interlaboratory variability has been addressed by international harmonization efforts.
For recombinant AMH under investigation as a contraceptive, preclinical data in mice suggest reversibility of ovarian suppression after cessation and no adverse effects on bone density, body weight, or estrous cycling. However, human safety data do not yet exist for exogenous AMH administration. Theoretical concerns include potential effects on non-reproductive AMH receptor-expressing tissues and long-term consequences of sustained follicular suppression. Clinical trials have not yet been initiated for contraceptive applications.
AMH measurement during pregnancy is not recommended as a clinical tool, as levels fluctuate and do not reliably predict obstetric outcomes. Oral contraceptive use modestly suppresses AMH levels, which should be considered when interpreting results.
Pharmacokinetic Profile
Anti-Müllerian Hormone (AMH) — Pharmacokinetic Curve
Research Protocols
oral
Oral contraceptive use modestly suppresses AMH levels, which should be considered when interpreting results.
Interactions
Peptide Interactions
Hormonal contraceptive use is associated with approximately 29.8% lower serum AMH concentrations compared to non-users. This decline is significant within 3 months of OC initiation and is reversible upon discontinuation. AMH testing results must be interpreted with OC use in context. Source: Meta-analysis, BMC Endocr Disord 2022.
What to Expect
What to Expect
Levels begin building after first administration; half-life of ~1-2 days in circulation means steady state reached over week 1-2
Initial response period as levels accumulate with repeated dosing
Steady-state concentrations expected after approximately 8 days of regular administration
Continued administration maintains therapeutic levels; effects may plateau at steady state
Quality Indicators
What to look for
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (12)
- [1]
- [4]Anderson RA et al. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer (2013)
- [6]Rey RA et al. Male hypogonadism: an extended classification based on a developmental, endocrine physiology-based approach. Andrology (2013)
- [5]Kano M et al. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci USA (2017)
- [2]La Marca A et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update (2010)
- [3]Durlinger AL et al. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction (2002)
- [8]Jacobs C et al. Serum anti-Müllerian hormone concentration and its association with reproductive outcomes. Fertil Steril (2023)
- [10]Tal R et al. Age-specific AMH percentiles and implications for fertility counseling. J Clin Endocrinol Metab (2024)
- [7]Lane AH et al. Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol (1999)
- [9]Penzias AS et al. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril (2020)
- [11]Sonigo C et al. Anti-Müllerian hormone in fertility preservation: clinical applications and limitations. Front Endocrinol (2022)
- [12]Visser JA et al. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol (2012)
Alpha-MSH (α-Melanocyte-Stimulating Hormone)
Alpha-MSH is an endogenous tridecapeptide derived from POMC processing that acts as a non-selective melanocortin receptor agonist, regulating pigmentation, inflammation, appetite, and sexual function through MC1R, MC3R, MC4R, and MC5R signaling.
Amylin (IAPP)
Amylin (Islet Amyloid Polypeptide, IAPP) is a 37-amino-acid pancreatic hormone co-secreted with insulin from beta cells. It regulates gastric emptying, promotes satiety, and suppresses glucagon. It is the parent compound for pramlintide (Symlin) and cagrilintide (in CagriSema).